SCHEMBL2984102

SCHEMBL2984102

Cc1ccc(C(=O)Nc2ccc(CCN3CCCC3)cc2)cc1Br

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.58
NPC1 O15118 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ALDH1A1 P00352 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
KDM4E B2RXH2 1/20 0.52
HTT P42858 2/20 0.52
GAA P10253 1/20 0.52
ABCB1 P08183 3/20 0.50
ABCG2 Q9UNQ0 3/20 0.50
EPHX2 P34913 2/20 0.49
KMT2A Q03164 4/20 0.48
MEN1 O00255 2/20 0.48
HPGD P15428 3/20 0.48
MAPT P10636 2/20 0.47
HTR1D P28221 1/20 0.47
HTR1B P28222 1/20 0.47
HTR2A P28223 1/20 0.47
TNF P01375 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13212024 0.83 HRH3 (0.63) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
Hydrochloric Acid SCHEMBL2907800 0.79 KDM4E (0.58) RAB9ANPC1KDM4EHTTGAA
SCHEMBL13683756 0.78 NPC1 (0.62) RAB9ANPC1ALDH1A1KDM4EABCB1
Iodide SCHEMBL5165156 0.78 KDM4E (0.57) RAB9ANPC1ALDH1A1KDM4EHTT
Hydrochloric Acid SCHEMBL2907065 0.78 KDM4E (0.57) RAB9ANPC1ALDH1A1KDM4EHTT
SCHEMBL2991638 0.76 ABCB1 (0.49) ABCB1ABCG2
SCHEMBL29374947 0.76 KMT2A (0.70) RAB9ASMN1; SMN2ALDH1A1TDP1KDM4E
SCHEMBL22516048 0.76 KMT2A (0.70) RAB9ASMN1; SMN2ALDH1A1TDP1KDM4E
SCHEMBL13683749 0.76 TNF (0.51) ALDH1A1KDM4EABCB1ABCG2KMT2A
SCHEMBL846574 0.75 BTK (0.65) RAB9ANPC1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150259329-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF INTRA CELLULAR THERAPIES INC (US) 2015-09-17 US disclosed
US-9056837-B2 Heterocycle compounds and uses thereof INTRA-CELLULAR THERAPIES, INC. (US) 2015-06-16 US disclosed
US-20130123269-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF INTRA-CELLULAR THERAPIES, INC. (US) 2013-05-16 US disclosed
US-8367686-B2 Heterocycle compounds and uses thereof INTRA-CELLULAR THERAPIES, INC. (US) 2013-02-05 US disclosed
US-20100173924-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF INTRA-CELLULAR THERAPIES INC. 2010-07-08 US disclosed
EP-2166858-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF Intra-Cellular Therapies, Inc. (US) 2010-03-31 EP disclosed
WO-2008153959-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF INTRA-CELLULAR THERAPIES, INC. (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259329-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF PYGB, BACE1, APP RAB9A 2953/4885NPC1 602/4885SMN1; SMN2 1778/4885
US-20100173924-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF PYGB, BACE1, APP RAB9A 2913/4885NPC1 549/4885SMN1; SMN2 1524/4885
US-20130123269-A1 NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF PYGB, BACE1, APP RAB9A 2953/4885NPC1 602/4885SMN1; SMN2 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.